RTTNews | Jun 11, 2021 10:03AM EDT

10:02 Friday, June 11, 2021 (RTTNews.com) - Shares of Vertex Pharmaceuticals Incorporated (VRTX) are down more than 8% Friday morning.

Thursday the company said it will not advance VX-864, the company's investigational drug in Phase 2 study for the treatment of people with alpha-1 antitrypsin deficiency (AATD), into late-stage development.

"Although results provide proof-of-mechanism, the magnitude of treatment effect observed in this study is unlikely to translate into substantial clinical benefit," Vertex said.

VRTX touched a 52-week low of $193 this morning. The stock is currently trading at $198.91

Read the original article on RTTNews ( https://www.rttnews.com/3201797/stock-alert-vertex-pharmaceuticals-down-on-dropping-plans-to-advance-vx-864-study-into-late-stage.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved